Scotland says yes to Eliquis and Incivo but declines Ozurdex and Xgeva
This article was originally published in Scrip
Executive Summary
Scotland's health technology appraisal body, the Scottish Medicines Consortium (SMC) has approved Vertex/Janssen-Cilag's hepatitis C drug Incivo (telaprevir) and Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) for preventing venous thromboembolism for use on the NHS. However, it turned down Allergan's Ozurdex (dexamethasone) for macular oedema following central or branch retinal vein occlusion (C/BRVO)and Amgen's Xgeva (denosumab) for preventing skeletal related events in adults with bone metastases from solid tumours.